NCT03268603 - Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

January 31, 2024

Study Completion Date

December 31, 2025

Conditions

ALSAmyotrophic Lateral Sclerosis

Interventions

DRUG

Autologous Adipose-derived Mesenchymal Stromal Cells

The investigational product consists of autologous adipose-derived Mesenchymal Stromal Cells (MSCs), suspended in 5-10 mL Lactated Ringer's. The MSC are provided in a sterile syringe labelled with appropriate patient and product identifiers ready for intrathecal injection.

Trial Locations (3)

32224

Mayo Clinic, Jacksonville

55905

Mayo Clinic in Rochester, Rochester

85259

Mayo Clinic, Scottsdale